These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15328422)

  • 1. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
    Bansback NJ; Young A; Brennan A
    Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 3. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A; Koenig AS; Bananis E; Singh A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An error in the revised anti-TNF therapy guidelines for adult RA.
    Deighton C; Ledingham J
    Rheumatology (Oxford); 2006 Sep; 45(9):1170. PubMed ID: 16769774
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
    Pressman Lovinger S
    JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis in the cytokine era: what rheumatologists need to know.
    Hamilton CD
    Arthritis Rheum; 2003 Aug; 48(8):2085-91. PubMed ID: 12905459
    [No Abstract]   [Full Text] [Related]  

  • 10. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M; Atagündüz P; Direskeneli H
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract]   [Full Text] [Related]  

  • 11. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative treatment strategies for patients with rheumatoid arthritis.
    van der Kooij SM; Allaart CF; Dijkmans BA; Breedveld FC
    Curr Opin Rheumatol; 2008 May; 20(3):287-94. PubMed ID: 18388520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE limits treatment choice for rheumatoid arthritis.
    Adam D
    Nurs Older People; 2008 Sep; 20(7):10-2. PubMed ID: 18853541
    [No Abstract]   [Full Text] [Related]  

  • 14. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 15. Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents.
    Goupille P; Pham T; Sibilia J; Mariette X
    Semin Arthritis Rheum; 2007 Dec; 37(3):202-3; author reply 203. PubMed ID: 17570470
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 18. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options.
    Turkiewicz AM; Moreland LW
    Arthritis Rheum; 2007 Apr; 56(4):1051-66. PubMed ID: 17393414
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Remission--therapy goal in rheumatoid arthritis].
    Z Rheumatol; 2007 Feb; 66(1):2 p following 87. PubMed ID: 17896425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.